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Background: Treatment of vomiting in acute gastroenteritis can increase the rate of successful
oral rehydration therapy (ORT) and lower the need for intravenous fluid administration. The aim of this[Electronic Physician 2010; 2: 95-101] Page 96
study was to investigate the role of ondansetron in decreasing vomiting and duration of hospitalization in
6 month to 14 year old children.
Methods: In 2010, a double blind randomized controlled trial was carried out based on 100
children between six months and 14 years old with acute gastroenteritis and vomiting. Each child satisfied
the inclusion criteria and agreed to participate in the study after receiving a complete explanation about
the study. Participants were randomly divided into two groups to either receive intravenous ondansetron
(single dose of 0.15mg/kg) or an intravenous placebo (5% dextrose water). The duration of hospitalization
and number of vomiting episodes were compared between the two groups 4 hours after treatment. Data
were analyzed using SPSS16 software.
Results: Duration of hospitalization was 38.30±18.62 hours in those receiving ondansetron and
45.10±25.79 hours in the control group. There was no statistically significant difference between the two
groups (P=0.352). The number of vomiting episodes was 0.06±0.23 in the ondansetron group and
0.58±0.90 in the control group. This difference is statistically significant (P=0.000). No adverse effects
were seen in either group relating to the drug.
Conclusions: This study demonstrated that intravenous ondansetron can effectively reduce the
frequency of vomiting associated with acute gastroenteritis. We recommend administration of
ondansetron for management of children with acute gastroenteritis but further studies with a larger sample
size would be beneficial.
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INTRODUCTION
Annually, acute gastroenteritis causes
150,000 to 170,000 hospitalizations and
accounts for about 13% of all
hospitalizations among children less than 5
years old in the United States (1). The
associated vomiting may cause physicians to
stop oral rehydration therapy (ORT) (2).
Treatment of vomiting can thus increase the
rate of successful ORT and lower the need
for intravenous fluid administration (3).
Ondansetron is thought to reduce frequency
of vomiting and reduce the need for
intravenous fluid and hospitalizations (4).
Studies on patients who failed to respond to
ORT show ondansetron to be effective in
reducing the risk of persistent vomiting and
hospital admission (5). Another randomized,
double blind, placebo-controlled trial
suggested that ondansetron is effective in
reducing the frequency of vomiting in
patients with gastroenteritis aged 5 months
to 8 years old in emergency departments at
both 8 and 24 hours after treatment (6).
However, it should be noted that these
findings result from randomized control
trials in emergency department patients and
thus cannot be accurately generalized to the
outpatient setting (4). Also, some recent
reviews have suggested that evidence for the
effectiveness of ondansetron in reducing the
number of episodes of vomiting is limited
and that ondansetron may increase the
incidence of diarrhea due to fluid and toxin
retention (7). Despite a number of clinical
trials showing the effectiveness of
ondansetron in decreasing vomiting (8), in
reducing the rate of fluid administration and
hospital admission (9) and in preventing
emesis (10), other studies did not find any
significant difference in the need for
hospitalization or return to emergency
department visits in comparison with
placebo or no intervention groups (11).
The aim of this study was to investigate the
duration of hospitalization and frequency of
vomiting in children with acute[Electronic Physician 2010; 2: 95-101] Page 97
gastroenteritis attending the emergency
department in the pediatric hospital of
Bandarabbas.
MATERIALS AND METHODS
This study is a pediatrics residency thesis
and is approved by the thesis committee of
the faculty of medicine in Hormozgan
University of Medical Sciences (HUMS).
The study was conducted in the only
pediatric hospital of Bandarabbas, which is
the capital city of Hormozgan Province in
southern Iran.
In 2010, a double-blind randomized
controlled trial was conducted based on 100
children aged six months to 14 years who
had agreed to participate in the study after
receiving a complete explanation about the
study. The participants were randomly
divided into two groups to either receive
intravenous ondansetron (single dose of
0.15mg/kg) or an intravenous placebo (5%
dextrose water).
Inclusion criteria were children of age six
months to 14 years who attended the
emergency department with acute
gastroenteritis and vomiting (having had
symptoms for less than 48 hours) and in
whom vomiting did not stop after 4 hours of
oral or intravenous fluid therapy. Exclusion
criteria were previous history of
hypersensivity to ondansetron, bloody
vomiting, previous history of abdominal
surgery, toxicity due to drugs or chemical
substances and other diseases such as
meningitis, sepsis, pancreatitis and testis
torsion.
Data on sex, weight, age, nutrition by breast
or formula milk, history of associated
diseases, past medical history and history of
hypersensivity to ondansetron were recorded
in a checklist.
Dehydration was classified according to
World Health Organization standards.
Patients were evaluated 4 hours before and 4
hours after treatment. Nurses randomly
divided the patients into either the control or
intervention group. The number of vomiting
episodes and duration of hospitalization
were recorded.
With the aim of comparing hospitalization
duration between groups, data were
analyzed with SPSS16 to obtain descriptive
statistics (mean, standard deviation and
frequency) and to carry out chi-square and
independent samples T-tests.
RESULTS
The experimental diet and the analyses are
illustrated in table 1 and 2. AD and TD of all
formulations was determined in a rat
bioassay. AD and TD in casein-diet rats 108
children were invited to participate in the
study, of which 100 (92.59%) were
included. Of those children who participated
in the study, 60 (60%) were male and 40
(40%) were female. The mean age of
participants was 20.66±17.91 months. The
mean number of vomiting episodes was
3.15±1.49 per child at the beginning of the
study.
27 (27%) children had mild dehydration, 71
(71%) had moderate dehydration and 2 (2%)
had severe dehydration. Eighty two (82%)
had received breast milk nutrition and 18
(18%) had received formula nutrition. 72
(72%) were living in cities and 28 (28%)
were living in rural areas. Table 1
summarizes the distribution of these[Electronic Physician 2010; 2: 95-101] Page 98
variables between the ondansetron and
control groups.
Duration of hospitalization was 38.30±18.62
hours in those receiving ondansetron and
45.10±25.79 hours in the control group.
There was no statistically significant
difference between the two groups
(P=0.352). The number of vomiting
episodes was 0.06±0.23 in the ondansetron
group and 0.58±0.90 in the control group,
yielding a statistically significant difference
in mean number of episodes (P=0.000). No
adverse effects were seen in either group
relating to use of the drug.
Table 2 compares the number of vomiting
episodes between the two groups and the
table 3 compares the number of vomiting
episodes and duration of hospitalization
between two groups when subdivided
according to demographic variables.
Table 1. Comparison of dehydration, nutrition, place of residence and type of diarrhea between ondansetron and
control groups
Ondansetron Control Total
Dehydration Mild 14 (28%) 13 (26%) 27 (27%)
Moderate 35 (70%) 36 (72%) 71 (71%)
Severe 1 (2%) 1 (2%) 2 (2%)
Nutrition Milk 42 (84%) 40 (80%) 82 (82%)
Formula 8 (16%) 10 (20%) 18 (18%)
Place of residence Urban 33 (66%) 39 (78%) 72 (72%)
Rural 17 (34%) 11 (22%) 28 (28%)
Type of diarrhea Watery diarrhea 41 (82%) 41 (82%) 82 (82%)
Loose stool 9 (18%) 9 (18%) 18 (18%)
Table 2. Comparison of the number of vomiting episodes between two groups
Ondansetron Control Total P Value
Number of vomiting
episodes
0 7 (94%) 32 (64%) 79 (79%) 0.002
1 3 (6%) 10 (20%) 13 (13%)
2 0 (0%) 5 (10%) 5 (5%)
3 0 (0%) 3 (6%) 3 (3%)
Total 50 (100%) 50 (100%) 100 (100%)[Electronic Physician 2010; 2: 95-101] Page 99
Table 3. Comparison of duration of hospitalization and mean vomiting episodes 4 hours after treatment according to
demographic factors between two groups
Duration of hospitalization (hours) Mean vomiting episodes
Number Mean SD P
value Mean SD P Value
Sex
Male
Ondansetron 34 39.32 18.86
0.399
0.058 0.23
0.001
Control 26 43.92 23.04 0.576 0.80
Female
Ondansetron 16 36.12 18.51
0.218
0.062 0.25
0.053
Control 24 46.37 28.93 0.583 1.01
Age
<1
years
Ondansetron 22 36.90 19.35
0.279
0.090 0.29
0.014
Control 23 44.21 24.83 0.521 0.73
1-2
years
Ondansetron 20 37.95 16.25
0.266
0.50 0.22
0.013
Control 19 46.63 30.07 0.684 1.05
>2
years
Ondansetron 8 43 23.56
0.928
0 0
0.207
Control 8 43 19.60 0.5 1.06
Nutrition
Milk
Ondansetron 42 38.83 18.62
0.072
0.047 0.21
0
Control 40 48.07 26.74 0.6 0.9
Formula Ondansetron 8 35.50 19.61 0.799 0.125 0.35 0.317
DISCUSSION
This study demonstrated that intravenous
ondansetron can effectively reduce the
frequency of vomiting associated with acute
gastroenteritis. Freedman et al. reported
similar results, and showed that a single
dose of ondansetron can reduce vomiting in
acute gastroenteritis patients (12) to the
extent that the majority of patients in their
study ceased vomiting after treatment with
ondansetron. In the present study 47 (94%)
children reported no further episode of
vomiting following the dose of ondansetron
and the other 3 children reported only 3
further episodes of vomiting.
However, Strok et al. found no significant
difference in the number of vomiting
episodes in the ondansetron, dexametasone
or normal saline groups (13). In a meta-
analysis in 2006, despite an increase in the
chance of relief from vomiting following the
use of ondansetron, routine use of
ondansetron was not recommended for acute
gastroenteritis (14).
Alhashimi et al. reported a small number of
clinical trials suggesting ondansetron was
effective in decreasing the number of
vomiting episodes in comparison to the[Electronic Physician 2010; 2: 95-101] Page 100
placebo (7). These trials also found no
significant difference in the duration of
hospitalization.
CONCLUSION
Our results show a significant difference in
the number of vomiting episodes after
treatment with ondansetron in comparison
with the placebo, in acute gastroenteritis in
children between 6 months and 14 years old.
We therefore recommend administration of
ondansetron for management of children
with acute gastroenteritis, but further studies
with a larger sample size would be
beneficial. Other factors, such as emergency
visit numbers and tolerance of oral
rehydration therapy, should be considered in
future studies.
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